Search tips
Search criteria 


Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
J Psychiatry Neurosci. 1995 July; 20(4): 265–270.
PMCID: PMC1188700

A comparison of placebo responders and nonresponders in subgroups of depressive disorder.


The objective of this study was to determine if the placebo treatment response varied in subgroups of depressed patients (single episode, recurrent, and double depression). Data from placebo-treated patients from seven placebo-controlled clinical trials were pooled and analyzed retrospectively. The placebo response rate was highest for females with a single episode of depression (66.7%) and lowest for females with recurrent depressive episodes (13.3%). Among patients experiencing their first episode, placebo responders had lower Hamilton Rating Scale for Depression (HAMD) total scores at baseline and lower ratings of pschomotor retardation than nonresponders. For patients having a recurrence of an episode, placebo responders had lower baseline ratings of somatic anxiety. The major finding was that patients suffering from their first depressive episode differed from patients with recurrent depressive episodes in the rate of placebo response, effect of gender, and the clinical symptoms that were associated with a positive placebo response.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (929K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Brown WA. Predictors of placebo response in depression. Psychopharmacol Bull. 1988;24(1):14–17. [PubMed]
  • Brown WA. Placebo as a treatment for depression. Neuropsychopharmacology. 1994 Jul;10(4):265–288. [PubMed]
  • Brown WA, Dornseif BE, Wernicke JF. Placebo response in depression: a search for predictors. Psychiatry Res. 1988 Dec;26(3):259–264. [PubMed]
  • Clayton PJ, Grove WM, Coryell W, Keller M, Hirschfeld R, Fawcett J. Follow-up and family study of anxious depression. Am J Psychiatry. 1991 Nov;148(11):1512–1517. [PubMed]
  • Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry. 1989 Jan;46(1):89–99. [PubMed]
  • Khan A, Dager SR, Cohen S, Avery DH, Scherzo B, Dunner DL. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology. 1991 Feb;4(2):125–130. [PubMed]
  • Keller MB, Shapiro RW. "Double depression": superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiatry. 1982 Apr;139(4):438–442. [PubMed]
  • Klerman GL. Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. Psychopharmacol Bull. 1986;22(1):25–29. [PubMed]
  • Kocsis JH, Frances AJ, Voss C, Mason BJ, Mann JJ, Sweeney J. Imipramine and social-vocational adjustment in chronic depression. Am J Psychiatry. 1988 Aug;145(8):997–999. [PubMed]
  • McConaghy N. Can reliance be placed on a single meta-analysis? Aust N Z J Psychiatry. 1990 Sep;24(3):405–415. [PubMed]
  • McDonald CJ, Mazzuca SA, McCabe GP., Jr How much of the placebo 'effect' is really statistical regression? Stat Med. 1983 Oct-Dec;2(4):417–427. [PubMed]
  • Morris JB, Beck AT. The efficacy of antidepressant drugs. A review of research (1958-1972). Arch Gen Psychiatry. 1974 May;30(5):667–674. [PubMed]
  • Quitkin FM, Stewart JW, McGrath PJ, Nunes E, Ocepek-Welikson K, Tricamo E, Rabkin JG, Ross D, Klein DF. Loss of drug effects during continuation therapy. Am J Psychiatry. 1993 Apr;150(4):562–565. [PubMed]
  • Rabkin JG, Stewart JW, McGrath PJ, Markowitz JS, Harrison W, Quitkin FM. Baseline characteristics of 10-day placebo washout responders in antidepressant trials. Psychiatry Res. 1987 May;21(1):9–22. [PubMed]
  • Rogers SC, Clay PM. A statistical review of controlled trials of imipramine and placebo in the treatment of depressive illnesses. Br J Psychiatry. 1975 Dec;127:599–603. [PubMed]
  • Scott J. Chronic depression. Br J Psychiatry. 1988 Sep;153:287–297. [PubMed]
  • Smith DG, Clemens J, Crede W, Harvey M, Gracely EJ. Impact of multiple comparisons in randomized clinical trials. Am J Med. 1987 Sep;83(3):545–550. [PubMed]
  • Stewart JW, McGrath PJ, Quitkin FM, Harrison W, Markowitz J, Wager S, Leibowitz MR. Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry. 1989 Dec;46(12):1080–1087. [PubMed]
  • Stewart JW, Quitkin FM, Liebowitz MR, McGrath PJ, Harrison WM, Klein DF. Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness. Arch Gen Psychiatry. 1983 Feb;40(2):202–207. [PubMed]
  • Svedmyr N. The placebo effect. Scand J Rehabil Med. 1979;11(4):169–172. [PubMed]
  • Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology. 1994 Aug;11(1):33–43. [PubMed]
  • Wilcox CS, Cohn JB, Linden RD, Heiser JF, Lucas PB, Morgan DL, DeFrancisco D. Predictors of placebo response: a retrospective analysis. Psychopharmacol Bull. 1992;28(2):157–162. [PubMed]
  • Wilkins W. Placebo problems in psychotherapy research. Social-psychological alternatives to chemotherapy concepts. Am Psychol. 1986 May;41(5):551–556. [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association